AARD · Aardvark Therapeutics, Inc.
Market Cap
$108.55M
Shares
21.88M
Volume · Oct 7
212.13K
Avg daily vol (3M)
210.22K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.96
Open$4.95
Day$4.69–5.33
52W close$3.48–17.41
Avg vol 30d124K
Short int425K · 1.9% float · 2.8d
Short vol72%
DataFeb 2025–Oct 2026
Filing10-Q · Aug 11
Up next
filed Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-70.4%
Trailing year
Short interest
1.9%
Latest settlement · 2.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−17%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
11%
near low
Momentum
relative strength
1-month return
+1%
trailing
6-month return
−1%
trailing
YTD return
−62%
this year
Relative strength
−11%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.94% of float · ▼ -16.7% MoM · 2.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
71 holders — mid 1-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Free cash flow
$-54.3M
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
11.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
11%
Bearish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-11% holders QoQ · +17 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.94% of float · ▼ -16.7% MoM · 2.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
71 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $3
Now $5 · 11%
Range high $17
vs 200-day avg -32%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents and short-term investments | $73.9M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AARD
this stock
Aardvark Therapeutics, Inc.
|
$108.55M | -62.2% | — | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.5% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.44B | +566.3% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.40B | -3.9% | +20.8% | 18.4 | 2.5% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AARD | -5.9% | +0.8% | -0.6% | -5.9% | -62.2% |
| SPY | +1.9% | +1.9% | +10.8% | +1.9% | +14.0% |
| vs SPY | -7.8% | -1.1% | -11.4% | -7.8% | -76.2% |